Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:160:A9937.

[Treatment options for resistant hypertension: from pseudoresistant to refractory hypertension]

[Article in Dutch]
Affiliations
  • PMID: 27142503
Review

[Treatment options for resistant hypertension: from pseudoresistant to refractory hypertension]

[Article in Dutch]
Jorie Versmissen et al. Ned Tijdschr Geneeskd. 2015.

Abstract

Resistant hypertension is defined as blood pressure above the target level despite treatment with 3 classes of antihypertensive drugs, including a diuretic. A large number of patients meeting the definition of TRH actually have 'pseudoresistant hypertension': there is either a secondary cause of the hypertension, non-adherence, high dietary salt intake, or use of interfering co-medication or recreational drugs. Treating pseudoresistant hypertension is just as challenging as 'true' resistant hypertension since causes of resistance cannot always be eliminated and elimination of causes will not necessarily lead to blood pressure normalization. It is estimated that only 10% of patients with TRH have 'true' resistant hypertension. A very small proportion of these patients is defined as having 'refractory hypertension' because their blood pressure still remains uncontrolled despite extending their medication to five or more agents, including an aldosterone receptor blocker. At present, non-pharmacological, invasive interventions should be considered only in patients with refractory hypertension.

PubMed Disclaimer

Similar articles

  • Treatment Resistant Hypertension.
    Egan BM. Egan BM. Ethn Dis. 2015 Nov 5;25(4):495-8. doi: 10.18865/ed.25.4.495. Ethn Dis. 2015. PMID: 26674466 Free PMC article. Review.
  • Current options for the treatment of resistant hypertension.
    Ahmed MI, Pisoni R, Calhoun DA. Ahmed MI, et al. Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1385-93. doi: 10.1586/erc.09.120. Expert Rev Cardiovasc Ther. 2009. PMID: 19900021 Review.
  • [Therapy Resistant and Refractory Hypertension].
    Düsing R. Düsing R. Dtsch Med Wochenschr. 2020 Jan;145(2):87-91. doi: 10.1055/a-1031-0612. Epub 2020 Jan 20. Dtsch Med Wochenschr. 2020. PMID: 31958855 German.
  • [Resistant hypertension].
    Feldstein CA. Feldstein CA. Rev Med Chil. 2008 Apr;136(4):528-38. Epub 2008 Jun 16. Rev Med Chil. 2008. PMID: 18769797 Review. Spanish.
  • The double challenge of resistant hypertension and chronic kidney disease.
    Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Ortiz A, Vanholder R, Wiecek A, Zoccali C, London GM, Stengel B, Fouque D; ERA-EDTA EURECA-m working group; Red de Investigación Renal (REDINREN) network; Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network. Rossignol P, et al. Lancet. 2015 Oct 17;386(10003):1588-98. doi: 10.1016/S0140-6736(15)00418-3. Lancet. 2015. PMID: 26530623 Review.

Cited by